IASLC WCLC 2021: Immune Checkpoint Inhibitor Survival Benefits Unaffected by Age in Advanced Non–Small Cell Lung Cancer
Biomarkers are needed to identify patients most likely to benefit from immunotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.